Clinical trial
Safety and Tolerability of Repeat Courses of IM Alefacept
NCT00233662 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00233662 |
|---|---|
| Title | Safety and Tolerability of Repeat Courses of IM Alefacept |
| Official title | An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients With Chronic Plaque Psoriasis |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | Alefacept |
| Enrollment | 400 |
| Start date | Dec 1, 2002 |
| Completion | Dec 1, 2005 |
| First posted | Oct 6, 2005 |
| Last update posted | Aug 23, 2023 |
| Countries | Austria, Canada, Denmark, France, Germany, Netherlands, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: